Circio Holding ASA announced that the completed phase 1/2 trial of ONCOS-102 in combination with Standard of Care (SoC) chemotherapy in malignant pleural mesothelioma (MPM) has been published in the Journal for ImmunoTherapy of Cancer (JITC), the prestigious immunology journal of the Society for Immunotherapy of Cancer (SITC). The study was a randomized phase 1/2 trial adding ONCOS-102 to SoC chemotherapy (pemetrexed/cisplatin) in first and later line MPM to assess safety, immune activation and clinical efficacy in a total of 31 patients. The ONCOS-102 and SoC combination showed a favorable safety profile, robust immune responses in injected tumors and a signal of clinical benefit.

In first line patients, the OS rate at 30 months was 34.1% for ONCOS-102-treated patients, which is a clear improvement over the first-line SoC-only control group where the OS rate was 0%.